

(Print or Type Responses)

1. Name and Address of Reporting Person* BALLJET JENNIFER			2. Issuer Name and Ticker or Trading Symbol NEOGENOMICS INC [NEO]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <div><div>Director</div><div>10% Owner</div><div>X Officer (give title below)</div><div>Other (specify below)</div></div> <div>VP and Chief Culture Officer</div>				
(Last) (First) (Middle) 12701 COMMONWEALTH DRIVE SUITE 9			3. Date of Earliest Transaction (Month/Day/Year) 03/01/2021							
(Street) FORT MYERS, FL 33913			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) <div><div>X Form filed by One Reporting Person</div><div>Form filed by More than One Reporting Person</div></div>				
(City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/01/2021		F		212 (1)	D	\$ 0	24,768	D	
Common Stock	03/02/2021		F		173 (2)	D	\$ 0	24,595	D	
Common Stock	03/02/2021		A		1,862	A	\$ 0	26,457	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$ 7.52							(3)	04/28/2022	Common Stock	7,000.00		7,000	D	
Stock Option (Right to Buy)	\$ 8.03							(4)	02/26/2023	Common Stock	33,334.00		33,334	D	
Stock Option (Right to Buy)	\$ 19.60							(5)	03/01/2024	Common Stock	17,496.00		17,496	D	
Stock Option (Right to Buy)	\$ 28.33							(6)	03/02/2027	Common Stock	15,006.00		15,006	D	
Stock Option (Right to Buy)	\$ 53.17	03/02/2021		A		10,551		(7)	03/02/2028	Common Stock	10,551.00	\$ 53.17	10,551	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other

BALLIET JENNIFER 12701 COMMONWEALTH DRIVE SUITE 9 FORT MYERS, FL 33913			VP and Chief Culture Officer	
--	--	--	------------------------------	--

## Signatures

/s/Jennifer Balliet		03/03/2021
<sup>**</sup> Signature of Reporting Person		Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2021 vesting of restricted stock.

(2) Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2021 vesting of restricted stock.

(3) On April 28, 2017, Ms. Balliet was granted 60,000 stock options. These options vested ratably over the first three anniversaries of the grant date.

(4) On February 26, 2018, Ms. Balliet was granted 72,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.

(5) On March 1, 2019, Ms. Balliet was granted 17,496 stock options. These options vest ratably over the first four anniversary dates of the grant date.

(6) On March 2, 2020, Ms. Balliet was granted 15,006 stock options. These options vest ratably over the first four anniversary dates of the grant date.

(7) On March 2, 2021, Ms. Balliet was granted 10,551 stock options. These options vest ratably over the first four anniversary dates of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.